Home
You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.
Latest Blood Sugar Articles
Popular Blood Sugar Articles
Highly Recommended Blood Sugar Articles
Study Will Compare Avandia’s Effect on Treatment of Type 2 Complications
SmithKline Beecham recently announced plans to initiate a major study to determine if early treatment with Avandia, Glucophage or a sulfonylurea improves and maintains blood sugar control in patients with type 2 diabetes, delays and/or prevents complications such as kidney disease and prevents decline in pancreatic beta-cell function.
According to a SmithKline Beecham news release, the study, called A Diabetes Outcome Progression Trial (ADOPT), will directly compare Avandia to Glucophage or a sulfonylurea. Glucophage and sulfonylureas are traditionally used medications that treat the symptoms of type 2 diabetes. They do not, however, directly target insulin resistance. The ADOPT study will be one of the longest and largest studies of people with type 2 diabetes initiated since the United Kingdom Prospective Diabetes Study.
This phase IV, randomized, double-blind, four-year study will be conducted in 300 sites worldwide and will enroll more than 3,500 recently diagnosed people with type 2 diabetes who have not been previously treated with an oral antidiabetes medication. Patients will be randomized to one of three treatment groups: Avandia, Glucophage or glyburide (glibenclamide in Europe).
The primary objective of the study is to evaluate and compare the metabolic effects of long-term treatment in patients with recently diagnosed type 2 diabetes. Endpoints include the long-term effects of each drug on:
- Durability of improvement in blood sugar control;
- Maintenance and restoration of pancreatic beta-cell function and effects on insulin sensitivity;
- Long-term safety, including liver, cardiovascular and hematological safety;
- Progression of microalbuminuria, which is an indicator of kidney disease and a cardiovascular risk factor;
- Other cardiovascular risk factors, including PAI-1, fibrinogen and C-reactive protein;
- Quality-of-life and pharmacoeconomic profiles.
Categories: Blood Sugar, Diabetes, Insulin, Medications Research, Type 2 Issues, Type 2 Medications
You May Also Be Interested In...
Click Here To View Or Post Comments
0 comments -
Jan 1, 2000
-
Diabetes Health
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.
-
Topics
- Diabetic / Diabetes Health
- Type 1 / 1.5 Diabetes
- Type 2 Diabetes
- Blood Glucose / Sugar
- High/Low Blood Sugar / Fast Acting Glucose
- Insulin- Pumps, Pens & Syringes
- Continuous Glucose Monitors, CGM, Infusion Sets
- Type 2 Medications
- Hyperglycemia
- Hypoglycemia
Email to a Friend
Send a link to this page to your friends and colleagues.